TWD 38.75
(-1.77%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 92.15 Million TWD | -24.58% |
2022 | 122.18 Million TWD | 394.82% |
2021 | 24.69 Million TWD | -57.92% |
2020 | 58.68 Million TWD | -9.16% |
2019 | 64.6 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q3 | 20.27 Million TWD | -46.02% |
2024 Q1 | 34.21 Million TWD | 35.87% |
2024 Q2 | 37.55 Million TWD | 9.76% |
2023 Q3 | 30.49 Million TWD | -6.0% |
2023 Q4 | 25.18 Million TWD | -17.41% |
2023 Q2 | 32.43 Million TWD | -3.48% |
2023 Q1 | 33.6 Million TWD | -21.14% |
2022 Q4 | 42.61 Million TWD | 0.0% |
2022 FY | 122.18 Million TWD | 394.82% |
2021 FY | 24.69 Million TWD | -57.92% |
2020 FY | 58.68 Million TWD | -9.16% |
2019 FY | 64.6 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
BIONET Corp. | 84.69 Million TWD | -8.807% |
Genetics Generation Advancement Corp. | 18.57 Million TWD | -396.081% |
Welgene Biotech Co.,Ltd. | -4.25 Million TWD | 2263.7% |
Puriblood Medical Co., Ltd. | -50.4 Million TWD | 282.83% |
TFBS Bioscience Inc. | -4.45 Million TWD | 2169.436% |